Solicitation #Solicitation TopicAward DateRRPV Member AwardedBase AwardFocus Area
RPP-24-04-NGVxNext Gen Vaccinations: Phase 2b Clinical Trial Execution06/13/2024Vaxart, Inc.$452,884,477Vaccines and Therapeutics
RPP-24-04-NGVxNext Gen Vaccinations: Phase 2b Clinical Trial Execution06/12/2024GeoVax, Inc.$24,321,841Vaccines and Therapeutics
RPP-24-04-NGVxNext Gen Vaccinations: Phase 2b Clinical Trial Execution06/04/2024CyanVac, LLC$40,167,897Vaccines and Therapeutics
RPP-24-04-NGVxNext Gen Vaccinations: Phase 2b Clinical Trial Execution06/03/2024CastleVax, Inc.$33,793,676Vaccines and Therapeutics
RPP-24-02-HomeFocusEnabling Technology – Decentralized Clinical Trial – Home Focus05/14/2024Allucent$25,514,420Vaccines and Therapeutics